Evaluation of gene and cell-based therapies for cardiac regeneration

Current Stem Cell Research and Therapy

Volumn 8, Issue 4, 2013, Pages 304-312

  Preda, Mihai Bogdan ^a,b   Valen, Guro ^b  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Cardiac regeneration; Cell therapy; Clinical trials; Gene therapy; Stem cells

Indexed keywords

ADENOVIRUS VECTOR; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; PLACEBO; PLASMID DNA; PLASMID VECTOR; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN D;

ACUTE HEART INFARCTION; ADULT STEM CELL; ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CARDIOVASCULAR GENE THERAPY; CELL TYPE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EMBRYONIC STEM CELL; FEASIBILITY STUDY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; HEART DEVELOPMENT; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE PERFUSION; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIC HEART DISEASE; MAMMAL; MESENCHYMAL STEM CELL; META ANALYSIS (TOPIC); MONONUCLEAR CELL; MULTICENTER STUDY (TOPIC); MYOBLAST; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; POSTNATAL GROWTH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATIVE MEDICINE; STABLE ANGINA PECTORIS; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; TRANSGENE;

ANIMALS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; GENETIC THERAPY; HEART; HUMANS; MYOCARDIAL INFARCTION; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

EID: 84887049514     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X11308040006     Document Type: Article

References (116)

1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8(1): 30-41.
2. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation 2010; 122(2): 173-83.
3. Owens AT, Jessup M. The year in heart failure. J Am Coll Cardiol 2012; 60(5): 359-68.
4. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and instent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107(21): 2677-83.
5. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009; 30(24): 2978-84.
6. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science 2002; 298(5601): 2188-90.
7. Flink IL. Cell cycle reentry of ventricular and atrial cardiomyocytes and cells within the epicardium following amputation of the ventricular apex in the axolotl, Amblystoma mexicanum: confocal microscopic immunofluorescent image analysis of bromodeoxyuridine-labeled nuclei. Anat Embryol (Berl) 2002; 205(3): 235-44.
8. Lepilina A, Coon AN, Kikuchi K, et al. A dynamic epicardial injury response supports progenitor cell activity during zebrafish heart regeneration. Cell 2006; 127(3): 607-19.
9. Jopling C, Sleep E, Raya M, et al. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature 2010; 464(7288): 606-9.
10. Kikuchi K, Holdway JE, Werdich AA, et al. Primary contribution to zebrafish heart regeneration by gata4(+) cardiomyocytes. Nature 2010; 464(7288): 601-5.
11. Peyton CC, Burmeister D, Petersen B, et al. Characterization of the early proliferative response of the rodent bladder to subtotal cystectomy: a unique model of mammalian organ regeneration. PloS one 2012; 7(10): e47414
12. Porrello ER, Mahmoud AI, Simpson E, et al. Transient regenerative potential of the neonatal mouse heart. Science 2011; 331(6020): 1078-80.
13. Cluzeaut F, Maurer-Schultze B. Proliferation of cardiomyocytes and interstitial cells in the cardiac muscle of the mouse during preand postnatal development. Cell and tissue kinet 1986; 19(3): 267-74.
14. Soonpaa MH, Kim KK, Pajak L, et al. Cardiomyocyte DNA synthesis and binucleation during murine development. Am J Physiol 1996; 271(5 Pt 2): H2183-9.
15. Leri A, Kajstura J, Anversa P. Mechanisms of myocardial regeneration. Trends Cardiovasc Med 2011; 21(2): 52-8.
16. Linke A, Muller P, Nurzynska D, et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci USA 2005; 102(25): 8966-71.
17. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114(6): 763-76.
18. Bearzi C, Rota M, Hosoda T, et al. Human cardiac stem cells. Proc Natl Acad Sci USA 2007; 104(35): 14068-73.
19. Chong JJ, Chandrakanthan V, Xaymardan M, et al. Adult cardiacresident MSC-like stem cells with a proepicardial origin. Cell stem cell 2011; 9(6): 527-40.
20. Unno K, Jain M, Liao R. Cardiac side population cells: moving toward the center stage in cardiac regeneration. Circ Res 2012; 110(10): 1355-63.
21. Jackson KA, Majka SM, Wang H, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107(11): 1395-402.
22. Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N Engl J Med 2002; 346(1): 5-15.
23. Bersell K, Arab S, Haring B, et al. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009; 138(2): 257-70.
24. Engel FB, Hsieh PC, Lee RT, et al. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci USA 2006; 103(42): 15546-51.
25. Kuhn B, del Monte F, Hajjar RJ, et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med 2007; 13(8): 962-9.
26. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009; 324(5923): 98-102.
27. Kajstura J, Urbanek K, Perl S, et al. Cardiomyogenesis in the adult human heart. Circ Res 2010; 107(2): 305-15.
28. Kajstura J, Rota M, Cappetta D, et al. Cardiomyogenesis in the aging and failing human heart. Circulation 2012; 126(15): 1869-81.
29. Senyo SE, Steinhauser ML, Pizzimenti CL, et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 2013; 493(7432): 433-6.
30. Graham RM, Harvey RP. The ontogeny of cardiac regeneration. Circ Res 2011; 108(11): 1304-5.
31. Valen G. Extracardiac approaches to protecting the heart. Eur J Cardiothorac Surg 2009; 35(4): 651-7.
32. Lyon AR, Sato M, Hajjar RJ, et al. Gene therapy: targeting the myocardium. Heart 2008; 94(1): 89-99.
33. Li Q, Guo Y, Xuan YT, et al. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res 2003; 92(7): 741-8.
34. Miao W, Luo Z, Kitsis RN, et al. Intracoronary, adenovirusmediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo. J Mol Cell Cardiol 2000; 32(12): 2397-402.
35. Chatterjee S, Stewart AS, Bish LT, et al. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation 2002; 106(12 Suppl 1): I212-7.
36. Stolberg SG. The biotech death of Jesse Gelsinger. N Y Times Mag 1999: 136-40, 49-50.
37. Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011; 124(3): 304-13.
38. Boodhwani M, Sellke FW. Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress. Antioxid Redox Signal 2009; 11(8): 1945-59.
39. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98(25): 2800-4.
40. Laitinen M, Makinen K, Manninen H, et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 1998; 9(10): 1481-6.
41. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100(5): 468-74.
42. Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000; 102(9): 965-74.
43. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized doubleblind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005; 45(7): 982-8.
44. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006; 13(21): 1503-11.
45. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105(11): 1291-7.
46. Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003; 42(8): 1339-47.
47. Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007; 50(11): 1038-46.
48. Stewart DJ, Kutryk MJ, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009; 17(6): 1109-15.
49. Kastrup J, Jorgensen E, Fuchs S, et al. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention 2011; 6(7): 813-8.
50. Kukula K, Chojnowska L, Dabrowski M, et al. Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am Heart J 2011; 161(3): 581-9.
51. Eckfeldt CE, Mendenhall EM, Verfaillie CM. The molecular repertoire of the 'Almighty' stem cell. Nat Rev Mol Cell Biol 2005; 6(9): 726-37.
52. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature 2008; 453(7193): 322-9.
53. Prockop DJ. Defining the probability that a cell therapy will produce a malignancy. Mol Ther 2010; 18(7): 1249-50.
54. van der Spoel TI, Jansen of Lorkeers SJ, Agostoni P, et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res 2011; 91(4): 649-58.
55. Zimmet H, Porapakkham P, Porapakkham P, et al. Short-and longterm outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail 2012; 14(1): 91-105.
56. Strauer BE, Steinhoff G. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice. J Am Coll Cardiol 2011; 58(11): 1095-104.
57. Wollert KC, Drexler H. Clinical applications of stem cells for the heart. Circ Res 2005; 96(2): 151-63.
58. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106(24): 3009-17.
59. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106(15): 1913-8.
60. Smits PC, van Geuns RJ, Poldermans D, et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol 2003; 42(12): 2063-9.
61. Schachinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44(8): 1690-9.
62. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364(9429): 141-8.
63. Schachinger V, Erbs S, Elsasser A, et al. Improved clinical outcome after intracoronary administration of bone-marrowderived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006; 27(23): 2775-83.
64. Huikuri HV, Kervinen K, Niemela M, et al. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008; 29(22): 2723-32.
65. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail 2010; 12(7): 721-9.
66. Beitnes JO, Hopp E, Lunde K, et al. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart 2009; 95(24): 1983-9.
67. Tendera M, Wojakowski W, Ruzyllo W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009; 30(11): 1313-21.
68. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrowderived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367(9505): 113-21.
69. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J 2011; 32(14): 1736-47.
70. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrowderived cells for cardiac repair: a systematic review and metaanalysis. Arch Intern Med 2007; 167(10): 989-97.
71. Martin-Rendon E, Brunskill SJ, Hyde CJ, et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 2008; 29(15): 1807-18.
72. Jeevanantham V, Butler M, Saad A, et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation 2012; 126(5): 551-68.
73. Clifford DM, Fisher SA, Brunskill SJ, et al. Long-term effects of autologous bone marrow stem cell treatment in acute myocardial infarction: factors that may influence outcomes. PloS One 2012; 7(5): e37373.
74. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119(Pt 11): 2204-13.
75. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110(10): 3499-506.
76. Hare JM, Traverse JH, Henry TD, et al. A randomized, doubleblind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54(24): 2277-86.
77. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011; 378(9806): 1847-57.
78. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiospherederived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012; 379(9819): 895-904.
79. Preda MB, Burlacu A. Electrocardiography as a tool for validating myocardial ischemia-reperfusion procedures in mice. Comp Med 2010; 60(6): 443-7.
80. [] Eckle T, Koeppen M, Eltzschig H. Use of a hanging weight system for coronary artery occlusion in mice. J Vis Exp 2011; (50).
81. Katz MG, Fargnoli AS, Pritchette LA, et al. Gene delivery technologies for cardiac applications. Gene Ther 2012; 19(6): 659-69.
82. Wright MJ, Wightman LM, Lilley C, et al. In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol 2001; 96(3): 227-36.
83. Tripathy SK, Svensson EC, Black HB, et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA 1996; 93(20): 10876-80.
84. Kalka C, Baumgartner I. Gene and stem cell therapy in peripheral arterial occlusive disease. Vasc Med 2008; 13(2): 157-72.
85. Bilbija D, Gravning JA, Haugen F, et al. Protecting the heart through delivering DNA encoding for heme oxygenase-1 into skeletal muscle. Life Sci 2012; 91(17-18): 828-36.
86. Czibik G, Gravning J, Martinov V, et al. Gene therapy with hypoxia-inducible factor 1 alpha in skeletal muscle is cardioprotective in vivo. Life Sci 2011; 88(11-12): 543-50.
87. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007; 13(4): 419-22.
88. McTiernan CF, Mathier MA, Zhu X, et al. Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Ther 2007; 14(23): 1613-22.
89. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302(5644): 415-9.
90. Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mole Ther 2008; 16(7): 1189-99.
91. Berns KI, Linden RM. The cryptic life style of adeno-associated virus. Bioessays 1995; 17(3): 237-45.
92. Zincarelli C, Soltys S, Rengo G, et al. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mole Ther 2008; 16(6): 1073-80.
93. Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adenoassociated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006; 99(4): e3-9.
94. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23(3): 321-8.
95. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008; 102(11): 1319-30.
96. Sorrentino SA, Bahlmann FH, Besler C, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptorgamma agonist rosiglitazone. Circulation 2007; 116(2): 163-73.
97. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37(5): 439-49.
98. Deb A, Wang S, Skelding KA, et al. Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients. Circulation 2003; 107(9): 1247-9.
99. Hofmann M, Wollert KC, Meyer GP, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111(17): 2198-202.
100. Schachinger V, Aicher A, Dobert N, et al. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation 2008; 118(14): 1425-32.
101. Forest VF, Tirouvanziam AM, Perigaud C, et al. Cell distribution after intracoronary bone marrow stem cell delivery in damaged and undamaged myocardium: implications for clinical trials. Stem Cell Res Ther 2010; 1(1): 4.
102. Hou D, Youssef EA, Brinton TJ, et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005; 112(9 Suppl): I150-6.
103. Kang WJ, Kang HJ, Kim HS, et al. Tissue distribution of 18FFDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J Nucl Med 2006; 47(8): 1295-301.
104. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11(4): 367-8.
105. Markel TA, Wang Y, Herrmann JL, et al. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol 2008; 295(6): H2308-14.
106. Yang Z, von Ballmoos MW, Faessler D, et al. Paracrine factors secreted by endothelial progenitor cells prevent oxidative stressinduced apoptosis of mature endothelial cells. Atherosclerosis 2010; 211(1): 103-9.
107. Li TS, Cheng K, Malliaras K, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol 2012; 59(10): 942-53.
108. Burlacu A, Grigorescu G, Rosca AM, et al. Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro. Stem Cells Dev 2013; 22(4): 643-53.
109. Loffredo FS, Steinhauser ML, Gannon J, et al. Bone marrowderived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011; 8(4): 389-98.
110. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-76.
111. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142(3): 375-86.
112. Vierbuchen T, Ostermeier A, Pang ZP, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463(7284): 1035-41.
113. Zhou Q, Brown J, Kanarek A, et al. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008; 455(7213): 627-32.
114. Qian L, Huang Y, Spencer CI, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012; 485(7400): 593-8.
115. Zhao T, Zhang ZN, Rong Z, et al. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474(7350): 212-5.
116. Araki R, Uda M, Hoki Y, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013; 494(7435): 100-4.